PIC
JWBK208-21 December 8, 2007 15:52 Char Count= 0
Soft Tissues 310
Other Muscle-related Lesions
r
Intramuscular myxoma (circumscribed, bland, hypocellular and ≈ avascular)
r
See sections below for proliferative myositis, intramuscular lipoma, hibernoma, haemangioma, an-
giomatosis and lipoblastomatosis
r
For rhabdomyoma see p. 79 and p. 233
Myofibroblast / Fibroblast
Myofibroblast Immunocytochemistry
r
+ve for vimentin and SMA ± desmin, ± smooth muscle myosin
r
Many myofibroblastic lesions are CD68 +ve (= ‘fibrohistiocytic’ differentiation)
r
CD117 (cytoplasmic blob +vity, not the membranous accentuation of GIST), CD171 −ve
General Points on (Myo)Fibroblastic Lesions
r
Post-op spindle cell nodule, nodular fasciitis and myositis ossificans: have many spindle myofibroblasts
r
Proliferative fasciitis / myositis and ischaemic fasciitis: have spindle and ganglion-like myofibroblasts
r
Spindle myofibroblasts: abundant eosinophilic fibrillary cytoplasm
r
Ganglion-like myofibroblasts: abundant basophil cytoplasm, vesicular nucleus, prominent nucleolus
r
d/dg collagenous fibroma vs. ‘burnt out’ fasciitis: fibroma has stellate cells and collagen but few mitoses
and is not spontaneously regressing
Post-Operative Spindle Cell Nodule
r
Clin.: tumour-like mass in vagina/endometrium/prostatic urethra/bladder 5 weeks–3 months post-op
r
Macro: oedematous, ulcerating, infiltrative borders
r
Micro: plump fibroblasts with large nucleoli, myxoid stroma, chronic inflam
y
infiltrate and upto
25/10hpf mitoses
r
d/dg: sarcomas: but post-op nodule cells are not hyperchromatic and have no abnormal mitoses
r
Immuno: myofibroblastic (vimentin, desmin and SMA +ve) ± CK (d/dg spindle cell carcinoma)
r
Related entity: pseudosarcomatous fibromyxoid tumour of the GU tract (no assoc
d
trauma / surgery)
Inflammatory Myofibroblastic Tumour and Inflammatory Pseudotumour
r
Synonyms/variants: inflammatory myofibroblastic tumour, plasma cell granuloma, fibroxanthoma (de-
pending on the relative prominence of fibroblasts, plasma cells and foamy M respectively)
r
Often discussed as a group but inflam
y
myofibroblatic tumour has prom. myofibroblasts with some
atypia and ALK-1 +vity and is a true neoplasm while the other variants (inflam
y
pseudotumours) are
either reactive or autoimmune (some may be part of IgG4-related disease, esp. if plasma cell granuloma
type)
r
Sites: lung, peritoneum, skin (d/dg angiolymphoid hyperplasia with eosinophilia), stomach, orbit (as
part of multifocal fibrosclerosis), bladder, peripheral liver (fibrohistiocytic), perihilar liver (plasma cell
granuloma)
r
Macro: several cm, well-circ., not encapsulated. In hollow organs it is polypoid ± ulceration
r
Plump active fibroblasts ± focal atypia, lymphocytes, plasma cells, M, foamy M
r
Variable mitotic rate
r
No well-structured collagenisation pattern ± hypocellular stroma ± necrosis ± calcification
r
Immuno: myofibroblastic (vimentin, SMA, ± CK, ± CD68), may be ALK +ve, CD34 is usu. −ve
r
Malignancy (= inflammatory fibrosarcoma):
is determined by behaviour rather than histology but often shows widespread pleomorphism
(but even bland cases may metastasise .
.
. some regard all cases as low grade malignant)
behaviour correlates with site: intra-abdominal ones may recur or metastasise; lower GU and
lung sites rarely recur or metastasise (NB: calcifying fibrous pseudotumour is benign)
other poor prognostics: ganglion-like cells, aneuploidy, p53 +vity
r
d/dg SFT: some regard calcifying fibrous pseudotumour (has marked hyaline, Ca
2+
± psammoma
bodies) as a variant of inflammatory myofibroblastic tumour. See SFT section, p. 324
r
d/dg spindle cell carcinoma (esp. if CK +ve) or carcinosarcoma (esp. if polypoid in hollow organ)
r
d/dg: other sarcoma: inflam
y
component, ALK +vity and lack of abnormal mitoses
r
d/dg other (ALK +vity helps): histiocytoma, plasmacytoma, myofibroblastoma